Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Copper Cu 64 anti-CEA monoclonal antibody M5A
- Development stage
- Phase 1
- Lead developer
- City of Hope Comprehensive Cancer Center
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Beta-minus Emitters → Radiopharmaceuticals, Positron Emitters → Radiopharmaceuticals, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
Copper Cu 64 anti-CEA monoclonal antibody M5A is a radiopharmaceutical agent composed of the humanized monoclonal antibody M5A targeting carcinoembryonic antigen (CEA), conjugated with the positron-emitting radioisotope copper-64. Upon administration, the M5A antibody specifically binds to CEA-expressing tumor cells. The attached Cu-64 enables detection and quantification of these cells using positron emission tomography (PET) imaging. This agent is primarily used for diagnostic imaging in patients with CEA-positive cancers such as colorectal cancer and medullary thyroid cancer[1][2][3][4]. The mechanism of action involves specific binding to CEA on tumor cells followed by PET-based visualization.
- Other names
- copper cu 64 anti-cea monoclonal antibody m5acopper-64 M5Acopper64 M5Acopper 64 M5A64Cu-M5A
Beyond the preview
Go deeper on Copper Cu 64 anti-CEA monoclonal antibody M5A.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Copper Cu 64 anti-CEA monoclonal antibody M5A.